Apple Inc. (NASDAQ:AAPL)

Apple Inc. is engaged in designing, manufacturing and marketing mobile communication and media devices, personal computers, and portable digital music players. The Company’s products and services include iPhone, iPad, Mac, iPod, Apple TV, a portfolio of consumer and professional software applications, the iOS and Mac OS X operating systems, iCloud, and a range of accessory, service and support offerings. It sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers. Apple Inc. is headquartered in Cupertino, California.

Apple Inc. (NASDAQ:AAPL)’s Financial Overview

Apple Inc. (NASDAQ:AAPL) declined -0.1% yesterday to close its trading session at $111.46. The company has 1 year Price Target of $131. Apple Inc. has 52-Week high of $119.86 and 52-Week Low of $89.47. The stock touched its 52-Week High on Dec 7, 2015 and 52-Week Low on May 12, 2016. The stock traded with the volume of 28.48 Million shares yesterday. The firm shows the market capitalization of $594.34 Billion.

Apple Inc. (NASDAQ:AAPL) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $1.67/share against the analyst consensus estimate of $1.66/share. The difference between the actual and expected EPS is $0.01 a share with a surprise factor of 0.6%.

The firm is trading with SMA20 of 1.19 Percent, SMA50 of -1.1 Percent and SMA200 of 7.58 percent. Apple Inc. has P/S value of 2.76 while its P/B value stands at 4.66. Similarly, the company has Return on Assets of 14.9 percent, Return on Equity of 35.6 percent and Return on Investment of 20.6 Percent. The company shows Gross Margin and Operating Margin of 39.1 percent and 27.8 percent respectively.

Many brokerage firms are involved in issuing their ratings on Apple Inc. (NASDAQ:AAPL). On 27-Oct-16 Hilliard Lyons Downgrade Apple Inc. Stock  to Long-term Buy. Another firm also rated the stock on 26-Oct-16 where Stifel Downgrade the stock to Hold.

The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 39 analysts offering 12-month price forecasts for Apple have a median target of 133.00, with a high estimate of 185.00 and a low estimate of 65.00. The median estimate represents a +19.33% increase from the last price of 111.46.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Provectus Biopharmaceuticals, Inc. (OTC:PVCT)

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. The company’s product portfolio consists of PV-10 Melanoma, PH-10 Psoriasis, PH-10 Atopic Dermatitis, PV-10 Breast Cancer, PV-10 Liver Metastasis and PV-10 Mechanism of Action which are in clinical trials. Provectus Biopharmaceuticals Inc., formerly known as Provectus Pharmaceuticals, Inc., is based in Knoxville, Tennessee.

Provectus Biopharmaceuticals, Inc. (OTC:PVCT)’s Financial Outlook

The 1 analysts offering 12-month price forecasts for Provectus Biopharmaceuticals Inc have a median target of 3.50, with a high estimate of 3.50 and a low estimate of 3.50. The median estimate represents a +23,078.81% increase from the last price of 0.02.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Provectus Biopharmaceuticals, Inc. has a Consensus Recommendation of NA. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock fell -44.07% and closed its last trading session at $0.02. The company has the market capitalization of $3.68 Million. The stock has 52-week high of $0.54 and 52-Week low of $0.01. The firm touched its 52-Week high on Apr 29, 2016 and 52-Week low on Nov 28, 2016. The company has volume of 26.31 Million shares. The company has a total of 243.9 Million shares outstanding.

The company has YTD performance of -96.13 percent. Beta for Provectus Biopharmaceuticals, Inc. stands at 0 while its ATR (average true range) is 0.01. The company has Weekly Volatility of 41.39%% and Monthly Volatility of 25.74%%.

Provectus Biopharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of -67.3%, Distance from 50-Day Simple Moving Average of -76.48 percent and Distance from 200-Day Simple Moving Average of -94.39%.

The Company currently has ROA (Return on Assets) of 0 percent, Return on Equity (ROE) of 0 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.